But the exact process by which uromodulin prevents inflammation had never been understood. Now an interdisciplinary team, drawn from three research groups at ETH Zurich together with researchers from the University of Zurich and the Children's Hospital Zurich, has filled this knowledge gap by investigating uromodulin's appearance and how the protein goes about neutralising uropathogenic E. coli. Their findings, which have been published in the journal Science, should help to develop new strategies for the treatment of urinary tract infections in the future.

A detailed look at how it works

First, the researchers analysed how the protein binds to the bacterial pili at the molecular level. "We already knew that a bond is formed and that this presumably plays a part in uromodulin's protective function, but nobody had studied this in greater detail," says Gregor Weiss, a doctoral student in molecular biology at ETH and one of the study's lead authors. Their biochemical investigations have now shown that the bacterial pili recognise certain sugar chains on the surface of the uromodulin and bind to them extremely readily and strongly.

Next, the team examined uromodulin using cryo-electron tomography, an imaging technique that produces three-dimensional views of the structure of proteins and cells with no need for chemical modification or dehydration. This showed them that uromodulin forms long filaments consisting on average of around 400 individual protein molecules strung together. And that each link of this protein chain contains the characteristic pattern of sugar chains to which bacterial pili like to bind.

Fruitful collaboration

Cryo-electron tomography was also the team's chosen technique for investigating at a larger scale what effect these properties have -- this time in the presence of the culprits, the uropathogenic E. coli bacteria. They discovered that the uromodulin filaments literally envelop the pathogen, and that a single uromodulin filament can dock with several pili of a bacterium. "This neutralises the pathogens," Weiss explains: "Once the bacteria are shielded in this way, they can no longer bind to the cells in the urinary tract, which means they can't cause infection." Under an optical microscope, the team also noted the formation of large clumps of hundreds of uromodulin filaments and E. coli cells, which are then presumably simply excreted with the urine.

Finally, the researchers checked to see whether all these processes they had observed in the laboratory also occur in patients. They analysed urine samples from infected patients provided by the Children's Hospital in Zurich and found exactly the same interactions between uromodulin and the pathogens. "Without interdisciplinary collaboration between different research groups and institutes, it would have been impossible to obtain this set of findings," stresses ETH Professor Martin Pilhofer, who led the electron tomography investigations.

Pointers for treatment and drug development

The research team's work offers pointers for how to treat and prevent urinary tract infections without using antibiotics. Until now, patients have often been given preparations that contain the sugar mannose. To a certain extent, these prevent the E. coli bacteria from attaching themselves to the cells of the urinary tract. "Thanks to our analyses, we now know that the bacterial pili recognise not only mannose but also other sugars present on uromodulin," says Jessica Stanisich, doctoral student and another lead author of the study. "This might indicate that treatment with combined sugar supplements would be more effective."

The new findings also help in the development of new active substances, adds ETH Professor Rudi Glockshuber. This is because during an infection the uropathogenic E. coli attach themselves to the same sugar chains on the cell surfaces of the urinary tract as on uromodulin. Pharmaceutical companies are looking to identify new active substances that will prevent precisely these interactions -- but this risks also disrupting the protective binding of uromodulin to the bacteria. "It would obviously be a highly undesirable side effect for a drug if that treatment simultaneously interfered with a natural protective function," Glockshuber says. However, the research team's analyses have now shown that the bonds between bacteria and uromodulin are extremely stable and cannot be broken down by active substances -- an important finding in the search for remedies for unpleasant urinary tract infections.

Story Source:

Materials provided by ETH Zurich. Original written by Santina Russo. Note: Content may be edited for style and length.

Journal Reference:

1. Gregor L. Weiss, Jessica J. Stanisich, Maximilian M. Sauer, Chia-Wei Lin, Jonathan Eras, Dawid S. Zyla, Johannes Trück, Olivier Devuyst, Markus Aebi, Martin Pilhofer, Rudi Glockshuber. Architecture and function of human uromodulin filaments in urinary tract infections. Science, 2020; eaaz9866 DOI: 10.1126/science.aaz9866